Quest Diagnostics shares gain momentum as the company reports a 10% revenue increase and lifts its 2026 outlook following a strong third-quarter performance.
Quest Diagnostics demonstrated robust financial performance in the third quarter, achieving a 10.0% year-over-year revenue increase to $3.10 billion and a 15.4% rise in adjusted diluted EPS to $3.00. Driven by strong organic revenue growth, the company has expressed confidence in its operational trajectory by raising its full-year 2026 revenue and EPS guidance.
Quest Diagnostics reported third quarter revenues of $3.10 billion, representing a 10.0% increase compared to 2025.
Reported diluted EPS was $2.78 (up 28.7%) and adjusted diluted EPS was $3.00 (up 15.4%) compared to the previous year.
Quest Diagnostics reported strong third-quarter results, with revenue climbing 10.0% to $3.10 billion and adjusted diluted EPS rising 15.4% to $3.00. Driven by robust organic growth, the company has officially raised its full-year 2026 financial guidance.
The company's performance was driven by strong organic revenue growth, which resulted in a 10.0% increase in total revenue to $3.10 billion.
Following the strong third-quarter results, Quest Diagnostics raised its full-year 2026 revenue and EPS guidance.